Quantcast
Home > Quotes > ABIO
x
ABIO

ARCA biopharma, Inc. Common Stock (ABIO) Quote & Summary Data

$0.6489
*  
0.0149
2.35%
Get ABIO Alerts
*Delayed - data as of Oct. 16, 2018 13:13 ET  -  Find a broker to begin trading ABIO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ABIO Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 0.641 / $ 0.649
1 Year Target
2
Today's High / Low
$ 0.6489 / $ 0.5924
Share Volume
164,600
50 Day Avg. Daily Volume
636,203
Previous Close
$ 0.634
52 Week High / Low
$ 2 / $ 0.45
Market Cap
9,035,170
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2.13

Intraday Chart

Shares Traded

Share Volume:
164,600
50 Day Avg. Daily Volume:
636,203

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
Earnings Per Share (EPS):
$ -1.08

Trading Range

The current last sale of $0.6489 is 44.20% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.6489 $ 2
 Low: $ 0.5924 $ 0.45

Company Description (as filed with the SEC)

Overview We are a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of each patient through the ability to classify individuals into subpopulations that differ in their susceptibility to a particular disease, in the biology and/or prognosis of those diseases they may develop, or in their response to a specific treatment. Our lead product candidate, Gencaro(TM) (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator that we are developing for the potential treatment of patients with chronic heart failure with reduced left ventricular ejection fraction, or HFrEF, who also have atrial fibrillation, or AF, or at risk of developing AF.  ... More ...  


Risk Grade

Where does ABIO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.6102
Open Date:
Oct. 16, 2018
Close Price:
$ 0.634
Close Date:
Oct. 15, 2018

Consensus Recommendation

Analyst Info